Liu Zhi-cun, Zhou Qiao-ling, Ouyang Chun, Deng Sheng-li
Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410078, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004 Dec;29(6):635-8.
To investigate the renal protective effect of specfic cyclooxygenase 2 inhibitor meloxicam on the renal of diabetic nephropathy rats.
Twenty-eight Sprague-Dawley (SD) rats with diabetic nephropathy by intraperitoneal injection of streptozotocin were randomly divided into 2 groups: diabetic nephropathy without any treatment (Group D,n = 14), and diabetic nephropathy treated with meloxicam. (Group M,n = 14). Another 12 normal rats were divided into normal control (Group N, n=12), and then Group M began to receive a blocker of cyclooxygenase 2 inhibitor, meloxicam [2 mg/(kg x d)]. Six weeks after the induction of DN, 24 h urine and blood samples were collected and kept at -70 degrees C. Then rats were killed. Their kidneys were removed and longitudinal halved. One half was placed and stored in fixation solution until COX-2 immunohistochemistry was determined.
The creatinine clearance rate, uria protein, and the expression of COX-2 in renal and urinary TXB2 in diabetic rats were significantly higher than in Group N. Meloxicam decreased uria protein or creatinine clearance rate significantly (P < 0.01). Immunohistochemical analysis revealed the decreased expression of COX-2 in the renal of Group M by the meloxicam treatment.
Meloxicam can protect diabetic kidney, somehow through deceasing the renal expression of COX-2.
探讨特异性环氧化酶-2抑制剂美洛昔康对糖尿病肾病大鼠肾脏的保护作用。
将28只经腹腔注射链脲佐菌素诱导的糖尿病肾病斯普拉格-道利(SD)大鼠随机分为2组:未接受任何治疗的糖尿病肾病组(D组,n = 14)和接受美洛昔康治疗的糖尿病肾病组(M组,n = 14)。另将12只正常大鼠分为正常对照组(N组,n = 12),然后M组开始接受环氧化酶-2抑制剂美洛昔康[2毫克/(千克·天)]治疗。糖尿病肾病诱导6周后,收集24小时尿液和血液样本并保存于-70℃。然后处死大鼠,取出肾脏并纵向切成两半。一半置于固定液中保存,直至进行COX-2免疫组化检测。
糖尿病大鼠的肌酐清除率、尿蛋白以及肾脏中COX-2的表达和尿TXB2均显著高于N组。美洛昔康显著降低了尿蛋白或肌酐清除率(P < 0.01)。免疫组化分析显示,美洛昔康治疗使M组肾脏中COX-2的表达降低。
美洛昔康可通过某种程度降低肾脏中COX-2的表达来保护糖尿病肾脏。